The Thai Journal of Veterinary Medicine


The pharmacokinetics of our previous prepared oxfendazole nanosuspension was studied in sheep to understand its enhancement of bioavailability. Ten sheep were randomly divided into two groups, each of which received a singledose (5mg/kg) oral oxfendazole nanosuspension and oxfendazole granules. After intragastric administration, oxfendazole rapidly reached peak concentrations of 11.25 μg/mL and 5.50 µg/mL at 5.6 h and 6.6 h in the nanosuspension group and granules group and the concentrations gradually reduced to below the detection limit at 96 h and 72h, respectively. The main pharmacokinetic parameters of oxfendazole after administration to the sheep: The Tmax, Cmax, AUClast, MRTlast, T1/2 and Ke of in nanosuspension were 5.6 h, 11.26 µg/mL, 179.22 µg*h/mL, 17.82 h, 87.22 h and 0.012 1/h, respectively, while the these main pharmacokinetic parameters in the OFZ granules group were 6.6 h, 5.50 µg/mL, 105.28 µg*h/mL, 16.55 h, 35.04 h, and 0.020 1/h, respectively. Compared with the granules group, the Cmax and AUClast of the nanosuspension group were increased by 2.05 and 1.70 times, respectively, and the Cmax and AUClast of the total active compound in the nanosuspension group were increased by 1.85 times and 1.71 times, respectively. These results suggest that the oxfendazole suspension might be an effective and promising formulation for use in sheep.



First Page


Last Page